2. UroToday Home
  3. Conference Highlights
  4. IBCN 2020

IBCN 2020: Drug Repurposing of Bladder Cancer Driven by Patients’ Proteomic Signatures

(UroToday.com) Dr. Marika Mokou, Biomedical Research Foundation Academy, Athens, Greece presented “Drug Repurposing of Bladder Cancer Driven by Patients’ Proteomic Signatures.”  The investigators characterized proteomic signatures from patients with non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC).  They identified druggable targets associated with reversal of high to low-risk molecular subtypes, including mTOR inhibitors and drugs targeting tubulin, caspases, and RAF.  


The candidate mTOR inhibitor WYE-354 was then investigated in bladder cancer cell lines in vitro, which resulted in decreased proliferation and colony formation.  The investigators report their high-throughput methodology for candidate drug identification through proteomic signatures.  These data have implications in the era of personalized medicine along the spectrum of stage, grade, and variant histologic differentiation of bladder cancer.

IBCN_2020_Faltas_3.png

Presented by: Marika Mokou, Ph.D., Biomedical Research Foundation Academy, Athens, Greece

Written by: Dr. Patrick Hensley, Urologic Oncology Fellow at MD Anderson Cancer Center, Twitter: @pjhensley11, with Ashish Kamat, MD, MBBS, President of The International Bladder Cancer Network (IBCN), The International Bladder Cancer Group (IBCG), and Professor of the Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, Twitter: @UroDocAsh, at the International Bladder Cancer Network (IBCN) Annual Meeting, #IBCN2020, October 17, 2020.